Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

Clinical trial NCT06282575 · RECRUITING

Trial details

NCT number: NCT06282575
Sponsor: Jazz Pharmaceuticals
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Biliary Tract Cancer

Start date: 2024-07-19
Primary completion: 2028-12-01
Enrollment: 286

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.